Floatz logo

Diammonium Glycyrrhizinate

Liver Inflammation

CttqSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Liver Inflammation cohort.

Asset / SponsorPhaseRating
MIDAZOLAM
Erasme University Hospital
Phase 4BB
Meperidine
Erasme University Hospital
Phase 4BB
Orlistat
St. Louis University
Phase 4BB
Entecavir
Cttq
Phase 4BB
URSODEOXYCHOLIC ACID
West China Hospital
Phase 4BB

View all 31 →

Same molecule, other indications

Diammonium Glycyrrhizinate is also rated in:

chronic hepatitis B virus infectionDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →
hepatocellular carcinomaDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →